JP2024502178A - Ｓｇｋ－１を阻害するためのピラゾロ［３，４－ｄ］ピリミジン－６－イル－スルホンアミド誘導体 - Google Patents

Ｓｇｋ－１を阻害するためのピラゾロ［３，４－ｄ］ピリミジン－６－イル－スルホンアミド誘導体 Download PDF

Info

Publication number
JP2024502178A
JP2024502178A JP2023541702A JP2023541702A JP2024502178A JP 2024502178 A JP2024502178 A JP 2024502178A JP 2023541702 A JP2023541702 A JP 2023541702A JP 2023541702 A JP2023541702 A JP 2023541702A JP 2024502178 A JP2024502178 A JP 2024502178A
Authority
JP
Japan
Prior art keywords
group
alkyl
compound according
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023541702A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024502178A5 (https=
JPWO2022150911A5 (https=
Inventor
ヴィダル、マルク
カリファ、マルア
マグワイア、マーティン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thryv Therapeutics Inc
Original Assignee
Thryv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thryv Therapeutics Inc filed Critical Thryv Therapeutics Inc
Publication of JP2024502178A publication Critical patent/JP2024502178A/ja
Publication of JP2024502178A5 publication Critical patent/JP2024502178A5/ja
Publication of JPWO2022150911A5 publication Critical patent/JPWO2022150911A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2023541702A 2021-01-13 2022-01-12 Ｓｇｋ－１を阻害するためのピラゾロ［３，４－ｄ］ピリミジン－６－イル－スルホンアミド誘導体 Pending JP2024502178A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163136782P 2021-01-13 2021-01-13
US63/136,782 2021-01-13
US202163262040P 2021-10-04 2021-10-04
US63/262,040 2021-10-04
PCT/CA2022/050038 WO2022150911A1 (en) 2021-01-13 2022-01-12 Pyrazolo[3,4-d]pyrimidin-6-yl-sulfonamide derivatives for the inhibition of sgk-1

Publications (3)

Publication Number Publication Date
JP2024502178A true JP2024502178A (ja) 2024-01-17
JP2024502178A5 JP2024502178A5 (https=) 2025-01-17
JPWO2022150911A5 JPWO2022150911A5 (https=) 2025-01-17

Family

ID=82446316

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023541702A Pending JP2024502178A (ja) 2021-01-13 2022-01-12 Ｓｇｋ－１を阻害するためのピラゾロ［３，４－ｄ］ピリミジン－６－イル－スルホンアミド誘導体

Country Status (8)

Country Link
US (1) US20240309005A1 (https=)
EP (1) EP4277905A4 (https=)
JP (1) JP2024502178A (https=)
KR (1) KR20230136622A (https=)
CN (1) CN121517419A (https=)
AU (1) AU2022208639A1 (https=)
MX (1) MX2023008219A (https=)
WO (1) WO2022150911A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250085708A (ko) * 2022-07-12 2025-06-12 쓰리브 테라퓨틱스 인크. N-[4-[4-[[2-(디메틸아미노)에틸]아미노]-3-메틸-1H-피라졸로[3,4-d]피리미딘-6-일)-2-플루오로페닐]-2,5-디플루오로벤젠설폰아미드의염 및 이의 결정 형태
WO2024015055A1 (en) * 2022-07-13 2024-01-18 Thryv Therapeutics Inc. Pyrazolo[3,4-d]pyrimidin-6-yl-sulfonamide derivatives for the inhibition of sgk-1 and treatment of cancer
KR102912267B1 (ko) * 2023-04-20 2026-01-15 한국화학연구원 신규한 헤테로고리 화합물 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 포함하는 바이러스성 질환의 예방 또는 치료용 약학적 조성물
CN121909195A (zh) * 2023-09-27 2026-04-21 百时美施贵宝公司 作为sgk1抑制剂的哌啶取代的吡唑并嘧啶衍生物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013063936A (ja) * 2011-09-20 2013-04-11 Sanofi Ｎ−［４−（１Ｈ−ピラゾロ［３，４−ｂ］ピラジン−６−イル）−フェニル］−スルホンアミド及び薬剤としてのその使用
JP2016514116A (ja) * 2013-03-13 2016-05-19 サノフイ Ｎ−（４−（アザインダゾール−６−イル）−フェニル）−スルホンアミド類及び医薬としてのそれらの使用
JP2020506877A (ja) * 2016-12-07 2020-03-05 ニュー エラ ファーマ，インク． Ｓｇｋ活性を調節するための化合物及び医薬組成物、並びにその方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3049085T (pt) * 2013-09-26 2021-10-01 Beth Israel Deaconess Medical Ct Inc Inibidores de sgk1 no tratamento da síndrome do qt longo

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013063936A (ja) * 2011-09-20 2013-04-11 Sanofi Ｎ−［４−（１Ｈ−ピラゾロ［３，４−ｂ］ピラジン−６−イル）−フェニル］−スルホンアミド及び薬剤としてのその使用
JP2016514116A (ja) * 2013-03-13 2016-05-19 サノフイ Ｎ−（４−（アザインダゾール−６−イル）−フェニル）−スルホンアミド類及び医薬としてのそれらの使用
JP2020506877A (ja) * 2016-12-07 2020-03-05 ニュー エラ ファーマ，インク． Ｓｇｋ活性を調節するための化合物及び医薬組成物、並びにその方法

Also Published As

Publication number Publication date
EP4277905A4 (en) 2025-01-01
CA3172186A1 (en) 2022-07-21
KR20230136622A (ko) 2023-09-26
US20240309005A1 (en) 2024-09-19
CN121517419A (zh) 2026-02-13
WO2022150911A8 (en) 2022-09-09
EP4277905A1 (en) 2023-11-22
WO2022150911A1 (en) 2022-07-21
MX2023008219A (es) 2023-08-24
AU2022208639A1 (en) 2023-07-20

Similar Documents

Publication Publication Date Title
CN113272301B (zh) 杂环类化合物、中间体、其制备方法及应用
JP5752232B2 (ja) プロテインキナーゼ阻害剤としての置換ピロロトリアジン化合物
TWI434846B (zh) 新穎化合物
JP6212527B2 (ja) Ａｔｒキナーゼのインヒビターとして有用なピラジン誘導体
CN105683188B (zh) 作为fgfr4抑制剂的稠环二环吡啶基衍生物
CN112638373A (zh) 细胞周期蛋白依赖性激酶抑制剂
JP2024502178A (ja) Ｓｇｋ－１を阻害するためのピラゾロ［３，４－ｄ］ピリミジン－６－イル－スルホンアミド誘導体
AU2018200536A1 (en) Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
WO2014149164A1 (en) Mk2 inhibitors and uses thereof
CA2739782A1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
CN107531695A (zh) Jak抑制剂
JP6559699B2 (ja) 置換含窒素複素環誘導体、それを含む医薬組成物及びその抗腫瘍性の適用
KR102470130B1 (ko) 아폽토시스 억제제
WO2014100533A1 (en) NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 δ/ε INHIBITORS
JP2019500389A (ja) 窒素含有縮合複素環化合物、製造方法、中間体、組成物および使用
JP7769648B2 (ja) スルホンアミド化合物
EP2935272A1 (en) Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors
JPWO2019189555A1 (ja) 複素環化合物
CN101090899B (zh) 用作蛋白激酶抑制剂的2,5和2,6双取代的氮茚类似物
AU2019344240B2 (en) Novel thiazole derivatives and pharmaceutically acceptable salts thereof
CA3172186C (en) Pyrazolo[3,4-d]pyrimidin-6-yl-sulfonamide derivatives for the inhibition of sgk-1
KR20250103668A (ko) 축합 이환 화합물
CN117062817A (zh) 用于抑制sgk-1的吡唑并[3,4-d]嘧啶-6-基-磺酰胺衍生物
WO2024015055A1 (en) Pyrazolo[3,4-d]pyrimidin-6-yl-sulfonamide derivatives for the inhibition of sgk-1 and treatment of cancer
CN120457122A (zh) 微管蛋白聚合抑制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260310